Skip to main content
Lyka Labs Ltd. logo

Lyka Labs Ltd. — Investor Relations & Filings

Ticker · LYKALABS ISIN · INE933A01014 LEI · 3358001RHQJBCTT1ER45 BSE.NS Manufacturing
Filings indexed 1,205 across all filing types
Latest filing 2021-07-08 Regulatory Filings
Country IN India
Listing BSE.NS LYKALABS

About Lyka Labs Ltd.

https://www.lykalabs.com

Lyka Labs Ltd. specializes in the development, manufacture, and marketing of pharmaceutical formulations and active pharmaceutical ingredients (APIs). The company maintains a diverse product portfolio spanning multiple therapeutic categories, including anti-infectives, dermatologicals, cardiovascular agents, and pain management. A significant area of expertise for the organization is lyophilization technology, enabling the production of high-quality injectable formulations. The company operates advanced manufacturing facilities designed to meet international quality standards, supporting its operations in both domestic and global markets. Its core activities encompass the production of various dosage forms such as tablets, capsules, ointments, and sterile injectables, with a particular focus on specialized segments like cephalosporins and critical care medications.

Recent filings

Filing Released Lang Actions
We attached herewith the Annual Report of Lyka Labs Limited for the financial year 2020-2021 for your information and record.
Regulatory Filings
2021-07-08 English
We wish to inform you that 42nd AGM of the Company is scheduled on Friday, 30th July, 2021 at 12.30 P.M. (IST) through Video Conference /Other Audio Visual Means. The Company is providing ....
Regulatory Filings
2021-07-08 English
Shareholders meeting
Regulatory Filings
2021-07-08 English
Trading Window
Regulatory Filings Classification · 95% confidence The document text contains only placeholders for images and no substantive text content. The true document length is only 164 characters, which is extremely short and contains no financial data, report content, or announcements. Given the lack of any textual information or report content, this document cannot be classified as a full report or detailed filing. It is most consistent with a Regulatory Filing (RNS) as a fallback category for miscellaneous or non-informative filings.
2021-06-30 English
This is to inform you that pursuant to the NSE circular no. NSE/CML/2019/11 and BSE circular no. LIST/COMP/01/2019-20 read with clause 4 of Schedule B of the SEBI (Prohibition of SEBI Insider ....
Regulatory Filings
2021-06-30 English
Loss of Share Certificates
Regulatory Filings
2021-06-21 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.